ALRN News and Press, Aileron Therapeutics Inc. From 06/02/20

Gainers: Ameri Holdings (NASDAQ: AMRH ) +152% . More news on: Ameri Holdings, Inc., Westwater Resources, Inc., Genius Brands International, Inc., Stocks on the move, , Read more ...

Nano cap Aileron Therapeutics ( ALRN +10.8% ) is up in early trade in reaction to positive preliminary data from a Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients from chemo-induced toxicity, also known as chemoprotection or myelopreservation. More news o...

Edwards Lifesciences (NYSE: EW ) -66% . More news on: Edwards Lifesciences Corporation, Iterum Therapeutics plc, Novus Therapeutics, Inc., Stocks on the move, , Read more ...

- - - Observed a protective effect against severe chemotherapy-induced anemia and thrombocytopenia across all dose levels - - - Management to host a conference call and webcast today at 8:30 a.m. EDT - - - WATERTOWN, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Aileron Therape...

These Penny Stocks Just Hit New 52-Week Highs. Are They Still A Buy? There’s no getting around the fact that penny stocks are high-risk equities. Just as quickly as they move up, they can come crashing down. In line with this, there’ve been plenty of higher-priced stocks that r...

WATERTOWN, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients with small cell lung cancer (SCLC...

Aileron Therapeutics (NASDAQ: ALRN ): Q1 GAAP EPS of -$0.24 misses by $0.04 . More news on: Aileron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Enrollment completed in the dose optimization part of the ongoing Phase 1b/2 clinical trial of ALRN-6924 as a chemoprotection agent in cancer patients - - - Scheduled to report interim results from the dose optimization part of the Phase 1b/2 trial 2 nd Quarter 2020, and planning f...

Presentation of interim results from the dose-optimization part of the Phase 1b myelopreservation study - - -  Final data readout from Phase 1b for both dose optimization and schedule optimization in Q4 2020 - - - Updated corporate presentation available on the Company’...

Aileron Therapeutics (NASDAQ: ALRN ): Q4 GAAP EPS of -$0.26 beats by $0.01 . More news on: Aileron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...